Recruiting Clinical Trials

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

By April 24, 2017 No Comments


Cervical Cancer|Pancreatic Cancer|Ovarian Cancer|Mesothelioma|Lung Cancer

Estimated Enrollment: 136

Age Group: 18 Years to 70 Years   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment

Study ID Numbers: 120111|12-C-0111

Study First Received: April 20, 2012

Last Updated: April 20, 2017

Estimated Primary Completion Date: December 31, 2018


Primary Outcome Measures:

Determine a safe dose of administration and determine if this approach will result in an objective tumor regression.|Determine the in vivo survival of CAR gene-engineered cells.

Sponsors and Collaborators:

National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)

Website Link:

Leave a Reply

Call Now